A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Phase: PHASE3
Conditions: Seasonal Allergic Rhinitis (SAR)
Sponsor: Glenmark Specialty S.A.

 
   
 
Confidential 
 
 
Page 1 of 1 
 
 
A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and 
Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo 
Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic 
Rhinitis (SAR)  
 
Identifiers                   NCT03463031 
Date of Document     18 July 2018